Kornimate/medical-research-clean huggingface dataset:
mental health, intellectual and neurodevelopmental disorder detection with artificial intelligence models

Conditions: Autism Spectrum Disorder; Depression - Major Depressive Disorder; Anxiety, Generalized; Bipolar Disorder (BD); Attention Deficit Hyperactivity Disorder (ADHD); Schizophrenia Spectrum &Amp; Other Psychotic Disorders; Post Traumatic Stress Disorder; Obsessive Compulsive Disorder (OCD)

Summary: this study investigates whether ai-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (adhd), autism spectrum disorder, bipolar disorder, generalized anxiety disorder, major depressive disorder, obsessive compulsive disorder (ocd), post-traumatic stress disorder (ptsd), and schizophrenia. we aim to develop tools that can support clinicians in making more accurate and efficient diagnoses.


Eligibility criteria:
inclusion criteria 1. participants aged between 16 and 60 years. 2. individuals currently undergoing or referred for clinical assessment of mental or behavioral health conditions (including but not limited to adhd, asd, bpad, gad, mdd, ocd, ptsd, ssd) 3. fluent in english 4. capable of providing informed consent, or in the case of minors, having a parent or legal guardian who can provide consent on their behalf. 5. access to a device (smartphone, tablet, or computer) with a microphone and stable internet connectivity, necessary for completing the speech tasks. exclusion criteria 1. individuals experiencing acute mental health crises or severe symptoms that would preclude meaningful participation in the study, including acute intoxication. 2. severe cognitive impairment or intellectual disability that would prevent understanding of the study procedures or completion of the speech tasks. 3. lack of fluency in english. 4. technical limitations: inability to access a suitable device or internet connection for completing the speech tasks

Keywords: artificial intelligence natural language processing acoustic analysis acoustic biomarkers clinical testing vocal biomarkers machine learning mental health speech analysis
differentiation of malig. & ben. solitary pulm. nodules & prediction of clin. outcome using perfus. analysis of dcemri

Conditions: Lung Neoplasms

Summary: the purpose of our study is to determine whether contrast-enhanced dynamic mri (dce mri) analysis of tumor angiogenesis and perfusion can be used as a reliable modality to differentiate benign from malignant solitary pulmonary nodules (spn) before surgical intervention, using kinetic model derived from dce mri, and further correlate if there is any positive correlation between angiogenesis factor (vascular endothelial growth factor vegf, microvessel density mvd); and if the perfusion parameters from dce mri can predict patients' outcomes and survival.

the solitary pulmonary nodule (spn) is a common finding in chest radiography. pulmonary nodules larger than 1cm indicative of malignancy or with indeterminate finding according to morphology criteria have to be defined by invasive methods such as biopsy or surgical excision, and benign pathology makes up 20-50% of those resected pulmonary lesions. the lesions not receiving surgical intervention often need imaging follow-up on a regular basis for a long period of time to monitor the stability of the finding. there are many reports regarding the mri perfusion analysis of neoplasms from many organs, including bone marrow, liver, breast, cervix, and they stressed not only on comparison between benignity and malignancy, but also on monitoring the treatment outcomes after neoadjuvant chemotherapy, radiation therapy or anti-angiogenic agent therapy \[7-15\]. dynamic contrast-enhanced mri (dce mri) is not a standard examination for spn, but there have been some data regarding the differentiation between malignant and benign spn using dce mri, with mri offering higher specificity compared to dynamic ct scan \[6, 7, 16\]. it was also reported that dce mri could delineate kinetic and morphologic differences in tumor angiogenesis and perfusion characteristics between malignant and benign pulmonary lesions with relatively high accuracy \[7, 16\]. the purpose of our study is to determine whether dce mri analysis of tumor angiogenesis and perfusion can be used as a reliable modality to differentiate benign from malignant spn before surgical intervention, using kinetic model derived from dce mri, and further correlate if there is any positive correlation between angiogenesis factor (vascular endothelial growth factor vegf, microvessel density mvd); and if the perfusion parameters from dce mri can predict patients' outcomes and survival.

Eligibility criteria:
inclusion criteria: * patients who have solitary pulmonary nodules in ct exclusion criteria: * patients who don't fit the above inclusion criteria

Keywords: lung neoplasms magnetic resonance imaging
application of one-handed lithotripsy in percutaneous nephrolithotomy

Conditions: Percutaneous Nephrolithotomy

Summary: percutaneous nephrolithotomy(pcnl) is a surgical method for upper urinary calculi.traditional percutaneous nephrolithotomy usually requires the lithotripsy with the left hand holding the nephroscope and the right hand adjusting the laser fiber,which requires a lot of practice to master this technique.the goal of this study is to explore the safety and effectiveness of the pcnl with one-handed lithotripsy technique

this is a key clinical research project of the university of south china(no.usckf201902k01).the goal of this study is to compare the safety,effectiveness and feasibility between the percutaneous nephrolithotomy with one-handed technique and the traditional percutaneous nephrolithotomy in the treatment of upper urinary calculi. it is a prospective, randomized controlled single center study that is conducted for 2 years anticipatively. the clinic physician is responsible for patient recruitment and allocation.for random allocation,participants are randomly grouped by coin toss method.participants with front side are assigned to experimental group,where they undergo pcnl with one-handed lithotripsy.participants with reverse side are assigned to control group and undergo traditional pcnl.the doctors managing the operations accept participants and execute the surgical treatments.all participants sign clinical-trial informed consent and surgical informed consent during the preoperative conversation.follow-up observation is conducted for 1 month after surgery. after completion of the study, we collect relevant clinical data from the participants. the primary and secondary outcomes are analyzed and compared between the two groups.

Eligibility criteria:
inclusion criteria: * participants who met the the applications of pcnl surgery in the 2019 chinese guidelines for the diagnosis and treatment of urological disease. * participants who agree to undergo one-hand lithotripsy. exclusion criteria: * obvious surgical contraindications, such as severe heart and lung insufficiency, abnormal coagulatory function. * confirmation by computerized tomography (ct) images and blood biochemical indicators of infectious stones or complex staghorn stones

Keywords: percutaneous nephrolithotomy one-handed lithotripsy urinary calculi traditional pcnl
evaluating an mhealth intervention for reducing alcohol use among adolescent and young adult cancer survivors

Conditions: Cancer; Alcohol Use

Summary: the objective of this study is to adapt and test the feasibility of a 4-week motivational interviewing mhealth intervention, tracking and reducing alcohol consumption (trac), to reduce alcohol use among adolescent and young adult (aya) cancer survivors during post-treatment survivorship. at the end of this study, the feasibility data gathered will inform a definitive randomized controlled trial of trac-aya to test the efficacy of the adapted intervention.

for this study, the investigators will adapt and pilot an existing mhealth intervention (trac) to reduce alcohol use among ayas as part of a randomized controlled trial. trac includes weekly phone sessions with an interventionist and incorporates smartphones for daily self-monitoring of alcohol use. upon enrollment, participants will be randomized into either the intervention (trac) arm or control (education and daily self-monitoring) arm. researchers will conduct the study in kentucky, which leads the nation in cancer incidence and mortality, has a higher incidence of aya cancers compared to other states, is 40% rural, and encompasses over 100 medically underserved areas. participants will be recruited from the university of kentucky markey cancer center and its affiliate institutions. preliminary data used for this study were collected from a study (pi: lauckner, k01aa02530) testing the trac intervention with people living with hiv/aids, which has shown promising preliminary results, with high feasibility, acceptability, and encouraging preliminary outcomes.

Eligibility criteria:
inclusion criteria: * diagnosed with cancer between age 15-39 * currently age 18-39 * 3 months-15 years post-treatment * meets criteria for risky alcohol use * reside in united states exclusion criteria: * severe psychopathology
gemcitabine and oxaliplatin in the management of metastatic pancreatic cancers with low expression of ercc1

Conditions: Metastatic Pancreatic Cancer; ERCC1

Summary: the goal of this clinical trial is to improve and personalize pancreatic cancer care to deliver the most effective therapy while avoiding unnecessary exposure to potential side effects. excision repair cross-complementation group 1 (ercc1) protein and mrna expression predicts response to oxaliplatin - patients whose cancers make small amounts of ercc1 are much more likely to respond to cisplatin than those whose tumors produce large amounts. the hypothesis is that the combination of gemcitabine and oxaliplatin is a uniquely effective regimen for patients with metastatic pancreatic cancer whose tumors have a low expression of ercc1.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic pancreatic adenocarcinoma * patients must not have had prior chemotherapy or biologic therapy for metastatic pancreatic cancer * prior adjuvant chemotherapy for completely resected disease or chemoradiotherapy for locally advanced disease is allowed but must have been administered \> 6 months prior to registration * ecog performance status of 0, 1, or 2 * adequate hematologic, hepatic and renal function exclusion criteria: * pregnant or nursing women * no other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years * patients must not have known brain metastases * any other condition that in the opinion of the investigator may render the patient at excessive risk for treatment complications

Keywords: pancreatic cancer ercc1 oxaliplatin gemcitabine
difference between pressing and vacuum techniques in fabrication of orthodontic aligners in cases with spacing: a cross-sectional study

Conditions: Orthodontic Aligners

Summary: this cross sectional study is aiming to compare 2 techniques of clear aligners fabrication identifying which is better.


Eligibility criteria:
inclusion criteria: * maxillary arch with moderate spacing. * full permenant dentition. exclusion criteria: * missing teeth. * any restorations.
efficacy of bupivacaine-magnesium combination versus bupivacaine alone in genicular nerve block

Conditions: Post Operative Pain

Summary: it is proved that the addition of magnesium sulfate to local anesthetics for neuraxial anesthesia improves the quality of analgesia and prolongs the duration of anesthesia . in-vitro and in-vivo studies have demonstrated that magnesium enhances the local anesthetics effect on peripheral nerves . no previous studies were conducted on magnesium sulfate as an adjuvant to the local anesthetic in genicular nerve block. hence, this study will be conducted to assess analgesic efficacy of magnesium sulfate when added to bupivacaine in ultrasound guided genicular nerve block


Eligibility criteria:
inclusion criteria: * american society of anesthesiologist (asa) i or ii physical status. * between 18 and 70 years of age. * both genders. * patients undergoing total knee replacement surgery. exclusion criteria: * patient refusal. * asa ⅲ and ⅳ patients. * known allergy to the study drugs. * hypermagnesemia. * central or peripheral neurological disease. * pregnancy. * drug or alcohol abuse. * localized infection at the site of the block. * bleeding disorder (platelets count less than 100,000 or international normalized ratio more than 1.4)
registry study for the observation of patients with esus/cryptogenic stroke

Conditions: Embolic Stroke of Undetermined Source

Summary: up to know, there is no clear diagnostic and therapeutic pathway for patients with embolic stroke of undetermined source (esus). this prospective registry study, which follows up adult esus patients for 36 months, is intended to provide important data for the detection of an individual approach in esus patients based on a structured diagnostic and therapeutic pathway.

the open-label, academic, prospective, monocentric, observational registry-study (catch-up-esus registry study) started in 01/2018. all esus-patients (≥18 years) treated in our hospital are included and will be followed up for three years. depending on age (\< 60 years or ≥ 60 years), the patients are processed according to a standardized treatment algorithm designed interdisciplinary by neurologists and cardiologists. an insertable cardiac monitor (icm) is implanted in all of them by default. patients \< 60 years without evidence of atrial fibrillation and co-existing pfo are planned for pfo closure within 6 months after stroke.

Eligibility criteria:
inclusion criteria: * embolic stroke of undetermined source or cryptogenic stroke; defined as: non-lacunar brain infarction without proximal arterial stenosis or cardioembolic source or other etiology (e.g. vasculitis, cervical artery dissection) * ≥18 years * written consent to participation in the study register by the patient or the legal guardian or authorised representative at the time of inclusion in the study

Keywords: stroke esus pfo pfo closure icm
efficacy and safety of sofosbuvir/ledipasvir ± ribavirin in japanese participants with chronic genotype 1 hcv infection

Conditions: Chronic HCV Infection

Summary: this study will evaluate the antiviral efficacy of sofosbuvir (sof)/ledipasvir (ldv) fixed-dose combination (fdc) tablet with or without ribavirin (rbv) in treatment-naive or treatment-experienced japanese participants with chronic genotype 1 hcv infection. participants receive 12 weeks of treatment and continue assessments during a 24-week posttreatment follow-up period.


Eligibility criteria:
inclusion criteria: * body weight ≥ 40 kg * hcv rna ≥ 10\^5 iu/ml at screening exclusion criteria: * current or prior history of any clinically-significant illness (other than hcv) * pregnant or nursing female or male with pregnant female partner * chronic liver disease of a non-hcv etiology * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv)
trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal vaccine in adults 65 years of age or older with prior pneumococcal vaccination

Conditions: Pneumococcal Disease

Summary: this phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination


Eligibility criteria:
inclusion criteria 1. male or female adults 65 years of age or greater. 2. adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product. 3. female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception. 4. male or female adults who meet 1 of the following: 1. vaccination with ppsv23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vpnc vaccination (cohort a). 2. vaccination with 13vpnc greater than or equal to 6 months prior to vaccination in the study, and no prior ppsv23 vaccination (cohort b). 3. vaccination with 13vpnc followed by ppsv23 (ppsv23 vaccination greater than or equal to 1 year prior to vaccination in the study) (cohort c). exclusion criteria 1. serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (copd) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study. 2. history of microbiologically proven invasive disease caused by s pneumoniae.
ptsd treatment and emotion regulation skills training for veterans with military sexual trauma (pe+er)

Conditions: Stress Disorders, Post-Traumatic; Anxiety Disorders; Mental Disorder; Traumatic Stress Disorder

Summary: prior research has found that veterans with military sexual trauma (mst) who have more difficulties with emotion regulation were more likely to drop out of ptsd treatment prematurely. the purpose of this pilot study is to determine whether integrating evidence-based emotion regulation skills training with a scientifically validated treatment for ptsd called prolonged exposure (pe), will enhance ptsd treatment retention and 'dose received' and subsequently improve treatment outcomes for mst-related ptsd and difficulties with emotion regulation. results from this project that examine the feasibility of integrating these two treatments will provide methodological evidence and justification for a randomized control trial, if warranted.

the purpose of this study is to learn ways to improve treatments for women with military sexual trauma (mst). the researchers want to learn whether combining evidence-based emotion regulation skills training with a trauma-focused therapy improves treatment outcomes. an evidence-based trauma treatment known as prolonged exposure will be used. emotion regulation skills will also be included in treatment. veterans with a positive or sub threshold diagnosis of ptsd who experienced a military sexual trauma (mst) will be included. participants will complete up to twelve 90 minute sessions of pe with dialectical behavior therapy (dbt) emotion regulation skills training followed by a post-treatment assessment. all aspects of the project including consent, baseline, treatment and follow-up will be completed either in person or via videoconferencing. fifteen participants will be enrolled.

Eligibility criteria:
inclusion criteria: * mst-related index event * diagnosis of ptsd related to mst assigned on the basis of the clinician administered ptsd scale (caps; weathers et al., 2013) * difficulties with emotion regulation as identified by the difficulties with emotion regulation scale (ders; gratz \& roemer, 2004; although there is no clinical cutoff for the ders, a total score of 99 is indicative of one standard deviation above average difficulties with emotion regulation for women). exclusion criteria: * having a household member who is already enrolled in the study * active psychosis or dementia at screening * suicidal ideation with clear intent * current moderate to severe substance use disorder * concurrent enrollment in a clinical trial for ptsd or depression.
inhaled budesonide for non-ventilated infants at high risk of bronchopulmonary dysplasia: the i-bud pilot study

Conditions: Bronchopulmonary Dysplasia

Summary: bronchopulmonary dysplasia (bpd) is one of the most important morbidities of preterm infants with a high incidence and significant impact on resource utilization and long-term outcome. systemic corticosteroids have been shown to be effective in the prevention of bpd through their potent anti-inflammatory effects but there are serious concerns on their potential detrimental effects on neurodevelopment of infants. in contrast, inhaled corticosteroids administered to ventilated infants are thought to be safer due to their topical effect but have not been shown to improve outcomes including bpd. to date, there have been few studies evaluating the effect of inhaled corticosteroids administered to non-ventilated infants for the prevention of bpd. hence, we are conducting a double-blind randomized controlled pilot trial to examine the impact of inhaled budesonide on non-ventilated infants. the study objectives, in a cohort of very preterm infants with signs of early bpd are: 1) to evaluate the effect of aerosolized budesonide on 'days on supplemental oxygen', and 2) to gain an estimate of the impact on bpd and 3) to assess the safety of the intervention in a small cohort of preterm infants. this will be a single-center randomized double-blind controlled pilot trial. we will recruit a total of 50 infants born at less than 30 weeks gestation who are on continuous positive airway pressure (cpap) with fraction of inspired oxygen ≥25% on day 14 of life or later. inhaled budesonide 1mg (intervention group) or normal saline (placebo) will be administered three times a day until the infants do not need cpap or supplemental oxygen or reach 36+0/7 weeks corrected gestational age. we will evaluate 'days on supplemental oxygen', bpd, re-intubation rates, days on mechanical ventilation and days on cpap as well as adverse outcomes. the prevention of bpd would have a significant positive impact on patient quality of life and medical resource utilization and costs. the study hypothesis is that inhaled budesonide on non-ventilated infants with early signs of bpd will reduce the 'days on supplemental oxygen' indicating a positive effect for the prevention of bpd. the result of this pilot study might also justify and support to proceed to a large confirmatory study to evaluate an effect of the intervention on bpd, in which the estimate of the impact on bpd gained in this pilot trial may be used to calculate a sample size.


Eligibility criteria:
inclusion criteria: * spontaneous breathing preterm infants on day 14 to day 42 of age * born at \< 30 0/7 weeks gestational age * requiring fio2 ≥ 25% on cpap including biphasic cpap or high flow nasal canula exclusion criteria: * presence of chromosomal defects or major congenital anomalies * presence of severe infections including sepsis, meningitis, pneumonia, systemic fungal infections * history of administration of systemic corticosteroids for pulmonary problems, not including that for hypotension

Keywords: budesonide inhalation premature infants
overactive bladder innovative therapy trial (orbit)

Conditions: Overactive Bladder

Summary: the purpose of this study is to compare percutaneous tibial nerve stimulation (ptns) to drug therapy for the treatment of symptoms of overactive bladder (oab).


Eligibility criteria:
inclusion criteria: * is at least 18 years of age * experiences oab with a voiding frequency of at least 8 times per day * is ambulatory and able to use a toilet independently and without difficulty exclusion criteria: * on oab pharmacotherapy within the previous month * primary complaint is stress urinary incontinence * has pacemaker or implantable defibrillator * has history of heart problems * has nerve damage or neuropathy * has gastric or urinary retention * has uncontrolled narrow-angle glaucoma * has known sensitivity to drug ingredients * is pregnant or planning to become pregnant during the trial

Keywords: oab symptoms of urgency, frequency, and urge incontinence